started · updated
FDA approves daraxonrasib for metastatic pancreatic cancer
The FDA has authorized the use of daraxonrasib, an oral drug designed to target RAS protein mutations, for adult patients with metastatic pancreatic adenocarcinoma. In the phase 3 RASolute 302 clinical trial involving 500 participants, the drug demonstrated a median survival of 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. The treatment also resulted in a 60% reduction in the risk of death.
Separately, medical experts are highlighting the impact of oral risdiplam for the treatment of Spinal Muscular Atrophy (SMA). Valeria Sansone, director of the NeMo Clinical Center, noted that the oral formulation facilitates greater patient autonomy and social reintegration. Unlike some other treatments, this medication does not require temperature-controlled storage and is easily transportable, allowing patients to manage their condition outside of a hospital setting.
Entities
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] The FDA authorized daraxonrasib for adult patients with metastatic disease who have received at least one line of systemic therapy or are ineligible for combination chemotherapy. quisalute.online
- [○ 1 SOURCE] The oral risdiplam treatment does not require temperature-controlled storage and is easily transportable. canaledieci.it
- [○ 1 SOURCE] Daraxonrasib reduced the risk of death by 60% compared to the control treatment. quisalute.online
- [○ 1 SOURCE] The RASolute 302 phase 3 clinical trial involving 500 participants showed a median survival of 13.2 months with daraxonrasib compared to 6.7 months with standard chemotherapy. quisalute.online
- [○ 1 SOURCE] The oral formulation of risdiplam for Spinal Muscular Atrophy (SMA) promotes patient autonomy and social reintegration. canaledieci.it